UNSPSC 51124305: Quinidine hydrochloride

This classification denotes a cation channel blocker and antimalarial agent with the molecular formula C20H24N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S4P5V5597B, chemically known as quinidine, monohydrochloride but more generally known as quinidine hydrochloride, which bears US NIH Compound Identifier 15474. European Medicines Agency schedules Quinidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15079MIG.

Most nations, for tariff and trade purposes, schedule quinidine hydrochloride under HS 29392000 and SITC 54142. As of Q4 2014, QUINIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCC2C(C1)C(CCN2)[C@@H]([C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)O.CL.

UNSPSC 51124305 Quinidine hydrochloride is a Commodity code covering pharmaceutical products purchased by state and local emergency services and healthcare providers for acute-care life support applications. The recent state and local procurement activity under this code reflects procurement of advanced cardiac and emergency medications in bulk quantities by municipal fire rescue services and related public health agencies. The City of Tampa's April 2026 procurement for Advanced Life Support Medications exemplifies the scope: Tampa Fire Rescue required sealed-bid supply of four emergency pharmaceutical line items (Labetalol, Epinephrine, Adenosine, and Diltiazem), with strict expiration-date requirements and rapid delivery windows. State and local issuers under this code include city purchasing departments acting on behalf of fire rescue operations and emergency medical services. Vendors must meet pharmaceutical compliance standards including OSHA Safety Data Sheets, accessibility conformance documentation (WCAG 2.2 Level AA and Section 508), and warranty provisions guaranteeing freedom from defects for a minimum of 365 days.

The City of Tampa in Hillsborough County, Florida is the only recent issuer in the available records. Tampa issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026 (posted April 24, 2026) and an estimated contract value of $40,000. The one-year base contract included renewal options for two additional one-year periods plus unilateral extension rights for up to three 30-day periods. The solicitation carried a Small Local Business Enterprise (SLBE) sheltered-market designation with a 5 percent bid discount for SLBE participation (not to exceed $10,000), requiring subcontractor forms (DMI-20 and DMI-40) within ten workdays of intent-to-award notice. Delivery was required within ten calendar days of order receipt, and all medications required minimum nine-month expiration dates from acceptance. Award was to be made to the lowest responsive, responsible bidder within 120 days of bid opening.